Publications by authors named "J P Bliss"
Despite MCT oil's potential antimicrobial benefits for gastrointestinal health, its effects on disrupting cariogenic pathogens on oral mucosal surfaces remain underexplored. This study evaluated the impact of MCT oil on the adhesion and invasion of and using planktonic and mucosal models. First, a planktonic model was used to assess the impact of various concentrations of MCT on the growth of and .
View Article and Find Full Text PDFPretreatment prognostication, on-treatment monitoring, and early detection of physiological symptoms are considerable challenges in cancer. We describe the feasibility of high-resolution wearable data (steps per day, walking speed) to longitudinally profile physiological trajectories extracted from Apple Health data in three patients with lung cancer from diagnosis through cancer treatment after obtaining informed consent. We used descriptive statistics to describe our approach of building longitudinal physiological profiles.
View Article and Find Full Text PDFBackground: Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer. Here we present the final 10-year analysis of the ALTTO trial.
Patients And Methods: The ALTTO trial (NCT00490139) is a prospective randomized, phase III, open-label, multicenter study that investigated the role of adjuvant chemotherapy and trastuzumab alone, in combination or sequentially with lapatinib.
Article Synopsis
- Clinical trials, essential for healthcare, also significantly contribute to climate change; researchers have developed a method to calculate their carbon footprint and applied it to 10 UK and international trials.
- Data on trial activities was collected from 10 trial units, evaluated for emission sources, and feedback was gathered on the carbon footprint calculation process.
- The carbon footprints of the trials varied widely, highlighting key areas for emissions reduction, with suggestions to incorporate carbon footprint considerations during the trial design phase.
Background: Early-life antibiotic exposure is disproportionately high compared to the burden of culture-proven early-onset sepsis (CP-EOS). We assessed the contribution of culture-negative cases to the overall antibiotic exposure in the first postnatal week.
Methods: We conducted a retrospective analysis across eleven countries in Europe, North America, and Australia.